PIK3CA and non-small cell lung carcinoma: This evidence highlights the ability of lentinan to sensitize pemetrexed‐resistant NSCLC cells by enhancing oxidative stress and inhibiting PI3K/AKT, suggesting its potential as a combinatorial treatment strategy.